Akers Biosciences, Inc. Notice of Half Yearly Results (9063V)
August 13 2015 - 1:01AM
UK Regulatory
TIDMAKR
RNS Number : 9063V
Akers Biosciences, Inc.
13 August 2015
Embargoed: 0700hrs, 13 August 2015
Akers Biosciences, Inc.
Notice of Second Quarter & First Half 2015 Results
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a medical device company focused on
reducing the cost of healthcare through faster, easier diagnostics,
announces that the Company will publish results on Friday, August
14, 2015 for the second quarter and first half periods ended June
30, 2015.
The Company will hold a conference call on Friday, August 14,
2015, at 2:00 p.m. BST (9:00 a.m. EDT). Akers Bio's Co-Founder and
Executive Chairman, Raymond F. Akers, Jr. PhD, and Vice President
of Finance, Gary Rauch, will host the call and be available during
the question and answer session.
To participate in the call from outside of the U.S., please dial
1-719-325-2464 (or from within the U.S. please dial 1-888-572-7034)
approximately 10 minutes prior to the scheduled start time. The
Conference ID is 3581038. Interested parties can also listen via a
live Internet webcast, which can be found through the Company's
website at http://ir.akersbiosciences.com/events.cfm or
alternatively at http://public.viavid.com/index.php?id=115956.
A replay of the call will be available from 6.30 p.m. BST (1:30
p.m. EDT) on August, 14, 2015, until 4:59 a.m. BST (11:59 p.m. EDT)
on August, 29, 2015. The number for the replay from outside of the
U.S. will be 1-858-384-5517 (or 1-877-870-5176 from within the
U.S.); the passcode for the replay will be 3581038. In addition, a
recording of the call will be available via the Company's website
at http://ir.akersbiosciences.com/events.cfm.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7016 9570
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBLGDIISBBGUD
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024